Heart disease is the leading cause of death in the U.S., accounting for 1 in 5 deaths. And 1 in 3 people will get shingles — ...

A new study suggests the shingles vaccine may reduce the risk of heart disease for up to eight years post-vaccination. A ...

The highly common herpes strain, also called varicella-zoster virus (VZV), can cause chickenpox in childhood and later ...

GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid ...

A study suggests that shingles vaccination may reduce heart disease risk by preventing a viral infection that can damage ...

Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine ...

The shingles vaccine has benefits that stretch beyond protecting older adults from the painful skin condition, a new study ...

New research looks at the emotional and physical repercussions of having your brain scanned for early signs of dementia.

Manufacturing Digital's top 10 biggest pharmaceutical manufacturers delivering innovative healthcare and improved patient ...

Discover Dynavax's impressive Q1 2025 earnings, driven by HEPLISAV-B's 36% revenue growth. Learn about pipeline milestones & market strategies.